General Catalyst Group Management LLC Takes $30.91 Million Position in Maze Therapeutics, Inc. $MAZE

General Catalyst Group Management LLC purchased a new position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,035,910 shares of the company’s stock, valued at approximately $30,912,000. Maze Therapeutics comprises 16.4% of General Catalyst Group Management LLC’s investment portfolio, making the stock its 4th biggest holding. General Catalyst Group Management LLC owned about 1.86% of Maze Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bank of America Corp DE purchased a new position in Maze Therapeutics during the 2nd quarter worth $9,585,000. Hhlr Advisors LTD. purchased a new stake in shares of Maze Therapeutics in the second quarter valued at about $10,922,000. Jupiter Topco LLC purchased a new stake in shares of Maze Therapeutics in the second quarter valued at about $101,764,000. ARCH Venture Management LLC acquired a new position in shares of Maze Therapeutics during the second quarter worth about $122,983,582,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Maze Therapeutics during the second quarter worth about $10,124,000.

Insider Transactions at Maze Therapeutics

In related news, CEO Jason V. Coloma sold 34,501 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total value of $1,034,339.98. Following the sale, the chief executive officer owned 23,337 shares in the company, valued at $699,643.26. This represents a 59.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total value of $205,050.00. Following the completion of the transaction, the insider directly owned 26,250 shares of the company’s stock, valued at $717,675. The trade was a 22.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 108,110 shares of company stock valued at $3,057,531 in the last quarter. 5.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

MAZE has been the subject of several analyst reports. BTIG Research reissued a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Monday. Finally, Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Price Performance

Shares of NASDAQ MAZE opened at $28.60 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. Maze Therapeutics, Inc. has a one year low of $13.77 and a one year high of $53.65. The firm has a market capitalization of $1.59 billion, a P/E ratio of -11.35 and a beta of 2.21. The company’s fifty day moving average is $28.70 and its two-hundred day moving average is $31.93.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting the consensus estimate of ($0.76). Analysts forecast that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.